Stealth Peptides has reported positive results from a Phase I clinical study to evaluate Bendavia, a novel compound that targets the mitochondria to treat ischaemia reperfusion injury.
The study enrolled healthy volunteers, who were given a single dose a of Bendavia administered as an intravenous infusion over an extended period.
Safety data from the clinical trial and preliminary results showed that Bendavia appears to be safe and well-tolerated at the dose evaluated, without any serious adverse events reported.
Pharmacokinetic analysis from related clinical studies also demonstrated highly predictable dose-proportional exposure of Bendavia among volunteers.
Stealth is currently initiating a multinational Phase II clinical study evaluating Bendavia as a treatment for ischemia reperfusion injury in patients experiencing acute ST–segment elevation myocardial infarction.
Ischaemia reperfusion injury is the tissue damage caused when blood supply returns to the tissue after a period of ischemia, and is a common complication in interventional procedures for acute myocardial infarction and coronary bypass surgery.
